Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects
暂无分享,去创建一个
L. Molnár | T. Solymosi | G. Filipcsei | J. McDermott | H. Glavinas | Réka Angi | Zsolt Ötvös | E. Duus | J. Orosz | Orsolya Basa-Dénes | Tamás Jordán | A. Ujhelyi | L. McKenzie | Dominic Capone | Nicola Whitfield | Lauren Shurety
[1] C. Prestidge,et al. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. , 2020, International journal of pharmaceutics.
[2] D. Walsh,et al. Dysphagia prevalence and predictors in cancers outside the head, neck, and upper gastrointestinal tract. , 2019, Journal of pain and symptom management.
[3] T. Solymosi,et al. Investigations of the mechanism behind the rapid absorption of nano‐amorphous abiraterone acetate , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[4] C. Stein,et al. The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers , 2017, Oncology and Therapy.
[5] K. Zejnullahu,et al. High‐Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.
[6] L. Molnár,et al. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements. , 2017, International journal of pharmaceutics.
[7] H. Wakabayashi,et al. Prevalence of sarcopenia and its association with dysphagia in cancer patients who require rehabilitation. , 2017, Journal of rehabilitation medicine.
[8] L. Molnár,et al. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect , 2017, Cancer Chemotherapy and Pharmacology.
[9] R. Goldwater,et al. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies , 2017, Clinical Pharmacokinetics.
[10] C. Kollmannsberger,et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.
[11] J. Go,et al. Pill Properties that Cause Dysphagia and Treatment Failure , 2015, Current therapeutic research, clinical and experimental.
[12] R. DiPaola,et al. Abiraterone in Prostate Cancer: A New Angle to an Old Problem , 2012, Clinical Cancer Research.
[13] Blair K. Brettmann,et al. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. , 2007, Molecular pharmaceutics.